BioMarin to acquire Alesta for $275M upfront to gain oral rare-disease drug
What's the deal? BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics to gain ALE1, a clinical-stage drug for hypophosphatasia (HPP), a rare genetic bone disease. Alesta shareholders will receive $275 million upfront plus up to $215 million tied to development and regulatory milestones.
What's the endgame? ALE1 is an orally active small molecule that could become the first oral therapy for HPP, a condition that impairs bone and tooth mineralization and can cause frequent fractures, early tooth loss, and muscle weakness. It is currently in a Phase 1/2a trial in healthy volunteers and adults with HPP.
Why now? BioMarin says the drug targets the central disease metabolite, PPi (inorganic pyrophosphate), offering a potential alternative to existing injectable therapies. The program will join BioMarin's Skeletal Conditions Business Unit after close.
Between the lines: Before closing, Alesta will spin out all non-ALE1 assets to a new entity, and its employees will transfer there. No Alesta staff will join BioMarin as part of the deal.
"ALE1 is a strong strategic fit for BioMarin, bringing a potential oral alternative to the injectable therapies available today," said Alexander Hardy, BioMarin's chief executive officer. He added that the asset "has the potential to reach our largest addressable patient population."
The terms: BioMarin plans to fund the deal with cash on hand and expects it to close this quarter, subject to customary conditions. Excluding the upfront payment, the transaction is expected to be modestly dilutive to 2026 results. Both boards have approved the deal.
"We chose to partner with BioMarin due to their deep commitment to people living with rare diseases," said Ilan Ganot, chief executive officer of Alesta Therapeutics, citing BioMarin's "global reach, scale, and proven expertise in rare disease drug development."
The signal: The acquisition reflects BioMarin's push to expand into larger rare-disease markets through clinical-stage deals, betting an oral option can compete with entrenched injectable treatments.
Image credit: foteih
Read more: PR Newswire
